Anti-leukemia activity of human gamma delta T cells

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 237-239

  Siegers, Gabrielle M ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adoptive cellular immunotherapy; Expansion protocol; Gamma delta T cells; In vivo bioluminescent xenograft model; Preclinical investigation

Indexed keywords

CD56 ANTIGEN; CONCANAVALIN A; DEATH RECEPTOR 4; FAS ANTIGEN; HLA ANTIGEN CLASS 1;

ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; APOPTOSIS; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; BIOLUMINESCENCE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL SELECTION; CELL SEPARATION; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; GAMMA DELTA T LYMPHOCYTE; HUMAN; LEUKEMIA CELL LINE; NONHUMAN; NOTE; PRIORITY JOURNAL; TUMOR XENOGRAFT; VDELTA1 GAMMA DELTA T LYMPHOCYTE; VGAMMA9VDELTA2 GAMMA DELTA T LYMPHOCYTE;

EID: 84886945604     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18231     Document Type: Note

References (10)

1. Ensslin AS, Formby B. Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst 1991; 83: 1564-9; http://dx.doi.org/10.1093/jnci/83.21.1564
2. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010; 37:1191-7; http://dx.doi.org/10.1016/j.ejcts.2009.11.051
3. Lucas C, Ingoure S, Soule E, Faria B, Audibert F, Blery M, et al. IPH1101, the First Specific {gamma} {delta} T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study. ASH Annual Meeting 2009; 114:583.
4. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and lowdose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010; 161: 290-7.
5. Lamb LS, Jr., Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ, et al. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 2001; 27:601-6; http://dx.doi.org/10.1038/sj.bmt.1702830
6. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC, et al. Human Vdelta1 gammadelta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 2011; 13:753-64.
7. + leukemia model. PLoS ONE 2011; 6: e16700; http://dx.doi.org/10.1371/journal.pone.0016700
8. Bartkowiak J, Kulczyck-Wojdala D, Blonski JZ, Robak T. Molecular diversity of gammadelta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia. Neoplasma 2002; 49:86-90.
9. 8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78; http://dx.doi.org/10.1016/S0022-1759(03)00265-5
10. Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P. Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol 2002; 215: 32-44; http://dx.doi.org/10.1016/S0008-8749(02)00001-1